ArticleESMO open2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
R Gutzmer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
42 papers cite it
this papertrialcites it